Abourbeh et al. (2015) reported an inverse correlation between [11C]erlotinib uptake in HCC827 tumor xenografts and injected carrier mass of unlabelled erlotinib, suggesting that saturation of EGFR-specific binding of [11C]erlotinib occurred. The gene discussed is EGFR; the disease is neoplasm.